---
schema_version: "secwatch.filing_event.v1"
accession: "0001388658-24-000156"
form_type: "8-K"
ticker: "IRTC"
cik: "0001388658"
company_name: "iRhythm Holdings, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:24:54.887479+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# iRhythm licenses BioIntelliSense sensor tech for up to $35M + royalties; reaffirms FY2024 guidance

## Summary
- iRhythm pays $15M upfront and up to $20M in milestone payments for an exclusive ACM license of pulse oximetry, accelerometry, and non-invasive BP tech.
- Also purchased $40M in convertible notes from BioIntelliSense; $20M of Milestone Notes will be cancelled upon regulatory milestones.
- Low single-digit royalties on home sleep testing product sales; license expires 10 years after first commercial sale per country.
- iRhythm expects a non-recurring acquired IPR&D expense in 2024 but no material additional development costs; FY2024 revenue, gross margin, and adjusted EBITDA guidance reaffirmed.
- Deal aims to expand iRhythm's ACM platform and enable entry into sleep apnea and other adjacent indications.

## SEC filing metadata
- accession: 0001388658-24-000156
- form_type: 8-K
- ticker: IRTC
- cik: 0001388658
- company_name: iRhythm Holdings, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388658/000138865824000156/0001388658-24-000156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388658/000138865824000156/irtc-20240830.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001388658-24-000156
- JSON: https://secwatch.observer/filing/0001388658-24-000156.json
- Plain text: https://secwatch.observer/filing/0001388658-24-000156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.